A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

China's biotech revival is pushing up prices of laboratory monkeys used in drug testing, as renewed R&D activity collides ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Alex Ossola: U.S. hiring slowed in January, but remained solid in the last jobs ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

Tobi is a crypto writer at Investopedia. He aims to simplify the complex concepts of blockchain and cryptocurrencies for the masses. Julie Bang/ Investopedia More people need better medicines, and ...

ATLATL, one of China’s leading biotech incubators, is seeking to bridge East-West innovation and tap into China's rapidly ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

XBI is a biotech-focused ETF offering equal-weight exposure to U.S. biotechnology companies. The SPDR S&P Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index. XBI ...

In this podcast, Motley Fool analysts Tim Beyers and Karl Thiel discuss: To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...